Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316430 | 1.00 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL21975301 | 0.98 | LMNA (0.64) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL11764950 | 0.95 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10736358 | 0.93 | LMNA (0.46) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL28922962 | 0.91 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL585190 | 0.91 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL2045830 | 0.90 | LMNA (0.48) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL18092218 | 0.88 | LMNA (0.64) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL1784683 | 0.85 | LMNA (0.38) | LMNABLMALOX15HIF1ATSHR | |
| SCHEMBL3408019 | 0.85 | HIF1A (0.45) | LMNABLMALOX15HIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-12-19 | — | — | US | claimed |
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-18 | — | — | US | claimed |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-21 | — | — | US | claimed |
| CN-117794504-A | Iris root extract, compositions and methods for dermatological use | 捷通国际有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024030367-A2 | FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2023162653-A1 | RESIST UNDERLAYER FILM FORMATION COMPOSITION | 日産化学株式会社 | 2023-08-31 | — | — | WO | disclosed |
| CN-116113659-A | Non-isocyanate polyurethane elastomer and composition containing the same | 纳米技术有限责任公司(以生物科学博士名义) | 2023-05-12 | — | — | CN | disclosed |
| CN-113348199-B | Branched organosilicon compounds, methods of making branched organosilicon compounds, and copolymers formed therewith | 美国陶氏有机硅公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114292171-A | Method for preparing tetrahydrogeranyl ketone by catalytic rectification reduction of diketene | 万华化学集团股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-0583971-A1 | Piperidine derivatives | SANKYO COMPANY LIMITED (JP) | 1994-02-23 | — | — | EP | disclosed |
| EP-0251827-B1 | NEW CYCLIC ETHER DERIVATIVES, THEIR PREPARATION AND THEIR USE | Sankyo Company Limited (JP) | 1993-09-15 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| CN-1059720-A | Radicicol derivatives, its preparation method and anti-tumor activity thereof | SANKYO CO (JP) | 1992-03-25 | — | — | CN | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| CN-1052481-A | Lipoid category-A with immunocompetence and anti-tumor activity is like thing | SANKYO CO (JP) | 1991-06-26 | — | — | CN | disclosed |
| US-4891363-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY LIMITED (JP) | 1990-01-02 | — | — | US | disclosed |
| US-4021461-A | INSECTICIDES | ZOECON CORPORATION (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | LMNA 2477/4885BLM 3348/4885PTPN1 4604/4885 |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | ELOVL6, ELOVL3, CPT1B | LMNA 2551/4885BLM 3418/4885PTPN1 4636/4885 |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | LMNA 2551/4885BLM 3418/4885PTPN1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.